KIC Ventures Offers Ownership Opportunity to Innovative Physicians: Raising $4 Million So Far
The Problem
Each year, over 266 million people worldwide suffer from degenerative spine disease, leading to a surge in spinal fusions. Traditional approaches often rely on pedicle screws and cages to limit natural spine movement, resulting in complications and revision surgeries. This increase in failed fusions has prompted Interventional Pain Management (IPM) physicians to manage these cases. Unfortunately, treatments such as opioids, injections, and spinal cord stimulation provide only temporary relief and pose addiction risks.
Similar to how interventional cardiologists have expanded their approach to cardiac care using LESS™ invasive techniques, IPM physicians are transitioning to early interventions for degenerative disc disease, aiming to reduce reliance on traditional fusions. Concurrently, spine surgeons are moving towards motion-preserving disc replacements to maintain natural spine function.
The Opportunity
A unique investment opportunity exists in motion-preserving technologies that restore natural spine anatomy and in developing proprietary LESS™ invasive techniques. These solutions allow spine surgeries to be safely performed in outpatient ambulatory surgery centers (ASCs) by IPM physicians, using awake sedation, which reduces risks associated with general anesthesia, blood transfusions, and extended recovery times. The simplicity, cost-effectiveness, and use of sterile, single-use equipment make this approach globally scalable.
Why KIC Ventures?
KIC Ventures is strategically positioned to address this opportunity with its proprietary LESS™ Exposure Spine Surgery (LESS) philosophy, focusing on motion preservation, early intervention, and LESS invasive solutions across its portfolio companies, AxioMed and NANISX.
Proven Track Record: Founded in 2000, incorporated in 2005, and with its private equity arm established in 2013, KIC Ventures marked its first exit with the sale of the MANTIS spinal system to Stryker in 2005. Today, it stands as the largest surgeon-led private equity firm focused on spine technologies.
AxioMed: Nearly 1,000 viscoelastic discs have been implanted worldwide, showing strong clinical outcomes with no reported device failures over more than a decade, supported by peer-reviewed studies.
NANISX: Initially met with skepticism for training IPM physicians in LESS™ technologies, NANISX has now trained nearly 400 IPM doctors, enabling thousands of successful spine surgeries in ASCs. The company has achieved consistent year-over-year growth with positive EBITDA and is developing new technologies set for release in 2025.
What Elon Musk Did and Why KIC Ventures Faced Skepticism
In 2004, Elon Musk invested $6.35 million in Tesla, despite doubts about the future of electric vehicles. Today, his stake in Tesla is worth over $120 billion. Similarly, KIC Ventures acquired AxioMed in 2013 amidst skepticism about viscoelastic discs in the U.S. market, given the dominance of fusion solutions and the lack of prior approvals. There were also doubts about NANISX's focus on training IPM physicians. However, increasing demand for motion-preserving solutions has validated KIC Ventures’ approach, positioning it for transformative growth.
Market Opportunity
The global spine surgery market, estimated at $20 billion, continues to expand due to an aging population and growing interest in motion-preserving treatments. AxioMed and NANISX are well-positioned to capture a substantial share of this dynamic market.
Series A Details
Target: $15 million
Raised: $4 million from 26+ investors
Valuation: $300 million for KIC Ventures
Minimum Investment: $50,000
Target Valuation & Return on Investment
KIC Ventures aims to reach a $5 billion valuation within five years, driven by key advancements:
AxioMed’s Anterior Lumbar Disc: Approaching FDA approval in 2025.
AxioMed’s Lateral Disc: Next in the pipeline.
Multilevel Cervical Disc: A milestone for broader adoption.
AxioMedX Smart Disc: Integrates real-time feedback for advanced spine care.
NANISX’s Continued Expansion: New technologies and training programs for IPM doctors and spine surgeons, fueling growth in outpatient interventional spine surgery.
Use of Funds
Funds from the Series A round will support:
Manufacturing AxioMed’s cervical and lumbar discs in Boston.
Establishing global distribution channels and strategic partnerships.
Conducting IDE clinical studies for lateral, multilevel cervical, and AxioMedX Smart Discs.
Expanding NANISX’s training programs and LESS™ Exposure technologies for IPM doctors and spine surgeons.
Recurring Returns vs. One-Time Exit
KIC Ventures is structured to provide multiple exit opportunities, ensuring recurring returns. While AxioMed is expected to drive primary growth, NANISX’s outpatient solutions will generate scalable revenue, supporting ongoing innovation.
KIC Ventures offers a rare opportunity to invest in the future of spine care innovation, with the potential for significant returns and a positive global impact. For more information, please visit www.KICVentures.com or contact Investor@KICVentures.com
This article is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities. Past performance is not indicative of future results.